logo
  

Rigel Completes Patient Enrollment In Phase 2 Trial To Evaluate Fostamatinib In COVID-19 Patients

Rigel Pharmaceuticals, Inc. (RIGL) announced the completion of patient enrollment in a multi-center phase 2 clinical trial to evaluate the safety of fostamatinib, the company's oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients. Treatment will be administered orally twice daily for 14 days. There will be a follow-up period to day 60.

Fostamatinib is marketed in the U.S. as TAVALISSE tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia.

Rigel expects to report topline data from the clinical trial in April 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT